Spots Global Cancer Trial Database for Treatment for Advanced B-Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment for Advanced B-Cell Lymphoma
Official Title: Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma
Study ID: NCT01859819
Study Description
Brief Summary: To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, \[Depocyt®\]) and reducing the dose of anthracycline (doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy backbone (Immunochemotherapy).
Detailed Description:
Eligibility
Minimum Age: 3 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Roswell Park Cancer Institute, Buffalo, New York, United States
New York Medical College, Valhalla, New York, United States
Levine Children's Hospital, Charlotte, North Carolina, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
University of Utah, Salt Lake City, Utah, United States
Contact Details
Name: Mitchell S Cairo, MD
Affiliation: New York Medical College
Role: PRINCIPAL_INVESTIGATOR
Name: Stanton Goldman, MD
Affiliation: Medical City Children's Hospital, Dallas
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
